Work

26654 Ixekizumab demonstrates greater medication adherence, persistence, and longer monotherapy duration than secukinumab, adalimumab, ustekinumab, and etanercept up to 3 years in the treatment of psoriasis: Real-world results

Year: 2021

Type: article

Study design: Observational Study

Source: Journal of the American Academy of Dermatology

DOI: 10.1016/j.jaad.2021.06.463

Authors: Andrew Blauvelt, Baojin Zhu, Mwangi Murage, Jiaying Guo, Terri Ridenour, Mingyang Shan, Russel Burge

Institutions: Oregon Medical Research Center, Eli Lilly (United States)

Language: English

Topic: Psoriasis: Treatment and Pathogenesis

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3193772661

FWCI: 0.183

Cites:

Cited by: 2

Related to: 10